Granules India shares in focus on EIR for Hyderabad facility

Granules India

Granules India share price will remain in focus on December 15 following the company received an Establishment Inspection Report (EIR) for its Hyderabad facility.

The company's a wholly owned subsidiary of Granules Life Sciences situated in Hyderabad, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA) for the first inspection conducted from July 28, 2025 to August 01, 2025.

This approval confirms the facility's compliance with FDA quality standards and regulatory requirements.

Granules Life Sciences is engaged in the manufacturing of PFI & finished dosages.

Catch all the market action on our live blog

Also, the company had achieved the highest “A” rating in Climate Change, reflecting a two-level improvement from the “B” rating received in 2024. Furthermore, the Company had achieved a “B” rating in Water Security and a “B-” rating in Forests in the first disclosure.

Last week, company's US step-down subsidiary, Granules Consumer Health, LLC, completed a GMP inspection by the USFDA with zero observations.

And also inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.

In the previous trading session, the share closed at Rs 574.50, up Rs 9.50, or 1.68 percent.

The share touched a 52-week high of Rs 621.10 and a 52-week low of Rs 412.05 on 07 January, 2025 and 07 April, 2025, respectively.

Currently, the stock is trading 7.5 percent below its 52-week high and 39.42 percent above its 52-week low.

The market capitalisation of the company stands at Rs 13,941.32 crore.